Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Louisiana Trastuzumab Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - LouisianaPolicy MA-241

    Trastuzumab Products

    Customize your policy alerts

    Sign up for blue cross blue shield - louisiana Policy MA-241 alerts

    Get alerted when Policy MA-241 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medicare Advantage coverage and prior authorization requirements for trastuzumab reference, biosimilar, and subcutaneous formulation products.

    Policy Summary
    PayerBlue Cross Blue Shield - Louisiana
    PolicyTrastuzumab Products
    Policy CodePolicy MA-241
    Change TypeNo material change
    Effective DateJan 1, 202743d
    Last ReviewOct 20, 2026
    Next Review DateOct 1, 2027
    Key ActionObtain prior authorization for all codes listed in this policy and submit documentation showing that coverage and patient-selection requirements are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Preferred trastuzumab biosimilars identified
    5Non-preferred products subject to selection criteria
    5HCPCS codes listed
    AllCodes requiring prior authorization
    90 daysTransition period for ongoing treatment

    Coverage Criteria

    Coverage eligibility and patient selection

    Coverage may be provided when all applicable requirements are met.

    • Coverage requirements

      • Benefits are available in the member's contract or certificate.
      • Applicable medical-necessity criteria and guidelines are met.
    • Patient-selection criterion

      • The patient has tried and failed trastuzumab-dttb (Ontruzant), trastuzumab-dkst (Ogivri), and trastuzumab-qyyp (Trazimera).

        Trial and failure may include intolerance or inadequate response.

      • Clinical evidence or patient history indicates that one or more of Ontruzant, Ogivri, or Trazimera would be ineffective or cause an adverse reaction to the patient.

    Not medically necessary

    The following products are not medically necessary when the patient-selection criterion is not met.

    Non-medically-necessary products: The patient-selection criterion is not met for trastuzumab (Herceptin), trastuzumab-anns (Kanjinti), trastuzumab-pkrb (Herzuma), trastuzumab-strf (Hercessi), or trastuzumab and hyaluronidase-oysk (Herceptin Hylecta).

    The patient-selection criterion requires failure of all three preferred products unless an accepted clinical exception applies.

    Medical necessity

    A service must meet all elements of the medical necessity definition.

    • The service is clinically appropriate in terms of type, frequency, extent, level of care, site, and duration.
    • The service is effective for the patient's illness, injury, or disease.
    • The service is not primarily for the personal comfort or convenience of the patient, physician, or other health care provider.
    • The service is not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results for the patient's illness, injury, or disease.

    Medicare Advantage coverage framework

    Coverage is determined under applicable Medicare authorities; internal coverage criteria may be used when those authorities do not fully establish coverage criteria.

    • Established coverage criteria are found in Medicare statutes, regulations, National Coverage Determinations (NCDs), and Local Coverage Determinations (LCDs).

      The Medicare Coverage Database should be consulted to determine whether an NCD or LCD addresses the specific service.

    • When applicable Medicare statutes, regulations, NCDs, or LCDs do not fully establish coverage criteria, internal coverage criteria may be developed and used as a summary of evidence, resources, and rationale supporting the criteria.

    Investigational or experimental services are excluded from coverage, including drugs, devices, procedures, or services provided under the investigational arm of a clinical trial or study, unless an applicable Medicare exception applies. Coverage may be limited to routine services for Category A IDE studies and to devices and related services for Category B IDE studies when not supplied by the trial sponsor.

    The listed non-preferred products—Herceptin, Kanjinti, Herzuma, Hercessi, and Herceptin Hylecta—are considered not medically necessary when the patient-selection requirement is not met. This requirement generally requires trial and failure of all three preferred products: Ontruzant, Ogivri, and Trazimera, unless an accepted clinical exception applies.

    A service must be clinically appropriate in its type, frequency, extent, level of care, site, and duration, and effective for the patient's illness, injury, or disease. Services primarily intended for the personal comfort or convenience of the patient, physician, or other healthcare provider do not meet the medical-necessity definition. Coverage may also be denied when the requested service is more costly than an alternative service or sequence of services that is at least as likely to produce equivalent therapeutic or diagnostic results.

    Initial Therapy Criteria

    Non-preferred product initial therapy

    For initial coverage of the non-preferred products, the following patient-selection criterion must be met.

    Patient-selection criterion

    • The patient has tried and failed all of trastuzumab-dttb (Ontruzant), trastuzumab-dkst (Ogivri), and trastuzumab-qyyp (Trazimera).All 3 preferred products

      Trial and failure may include intolerance or inadequate response.

    • Clinical evidence or patient history suggests that Ontruzant, Ogivri, or Trazimera will be ineffective or cause an adverse reaction to the patient.

    Continuation and Transition Criteria

    Transition of ongoing therapy

    For an ongoing course of treatment when a member changes from another health plan to Blue Advantage:

    90-day transition of ongoing treatment

    • Blue Advantage may honor the previous health plan's authorization for the same service under the same type of in-network benefit.90 days
    • The member or provider provides documentation of the previous health plan's authorization for the ongoing course of treatment.
    • The services provided for the course of treatment are otherwise covered under the Blue Advantage health plan.

    Preferred Product Sequence

    StepRequired trial and failureApplies before coverage ofExceptions and clarifications
    1Try and fail all three preferred products: Ontruzant, Ogivri, and Trazimera. Trial and failure may include intolerance or inadequate response.Herceptin, Kanjinti, Herzuma, Hercessi, or Herceptin HylectaThe requirement may be waived when clinical evidence or patient history indicates the preferred products would be ineffective or cause an adverse reaction. Coverage of a biosimilar as an alternative to its reference product is not considered step therapy.

    Policy Coding

    CPT CodesCPT
    No codes listed
    Covered HCPCS CodesHCPCSCovered
    J9355J9355
    J9356J9356
    Q5113Q5113
    Q5117Q5117
    Q5146Q5146
    ICD-10 DiagnosisICD-10
    All related diagnosesAll related diagnoses

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for all codes listed in this policy before services are provided.

    • Submit prior authorization for every listed code.
    • Authorization supports appropriate utilization and alignment with current clinical guidelines.
    Prior Authorization

    Utilization Management Applies to All Listed Codes

    Each listed code is subject to the Health Plan’s utilization-management requirements. Do not assume that a code is exempt from prior authorization.

    • Apply the prior-authorization requirement to every listed code.
    • Obtain approval before treatment or billing when required.

    Trastuzumab Biosimilar Coverage

    Billing Rule

    Ontruzant: preferred biosimilar

    Ontruzant is a preferred trastuzumab biosimilar to Herceptin. Coverage of non-preferred trastuzumab products requires a trial and failure of Ontruzant unless clinical evidence or patient history indicates it would be ineffective or cause an adverse reaction.

    Billing Rule

    Ogivri: preferred biosimilar

    Ogivri is a preferred trastuzumab biosimilar to Herceptin. Coverage of non-preferred trastuzumab products requires a trial and failure of Ogivri unless clinical evidence or patient history indicates it would be ineffective or cause an adverse reaction.

    Billing Rule

    Trazimera: preferred biosimilar

    Policy Definitions

    Biosimilar
    DefinitionA biological product that is highly similar to an existing FDA-approved reference product.
    Clinical standardThe product has no clinically meaningful differences from the reference product in safety or effectiveness.
    Trastuzumab applicationOgivri, Kanjinti, Trazimera, Herzuma, Hercessi, and Ontruzant are biosimilar products compared with Herceptin.
    Reference product
    Reference productHerceptin is the FDA-approved reference trastuzumab product.
    Comparison roleListed trastuzumab biosimilars are compared against Herceptin.
    Formulation distinction

    Clinical Background

    Trastuzumab products are FDA-approved biologic therapies used for a variety of oncolytic conditions, with additional off-label uses supported by accepted clinical guidelines. Herceptin is the FDA-approved reference product; Ogivri, Kanjinti, Trazimera, Herzuma, Hercessi, and Ontruzant are biosimilars with no clinically meaningful differences from Herceptin. Herceptin Hylecta is a subcutaneous formulation of Herceptin with clinical-trial evidence of similar efficacy and safety to intravenous Herceptin.

    Policy Summary
    PayerBlue Cross Blue Shield - Louisiana
    PolicyTrastuzumab Products
    Policy CodePolicy MA-241
    Change TypeNo material change
    Effective DateJan 1, 202743d
    Last ReviewOct 20, 2026
    Next Review DateOct 1, 2027
    Key ActionObtain prior authorization for all codes listed in this policy and submit documentation showing that coverage and patient-selection requirements are met.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation and Transition CriteriaPreferred Product SequencePolicy CodingAuthorization and Documentation RequirementsTrastuzumab Biosimilar CoveragePolicy DefinitionsClinical Background
    Step Therapy

    Preferred Biosimilar Sequence

    For non-preferred trastuzumab products, document that the patient has tried and failed all required preferred biosimilars before requesting coverage.

    • Required sequence: trastuzumab-dttb (Ontruzant), trastuzumab-dkst (Ogivri), and trastuzumab-qyyp (Trazimera).
    • Trial and failure may include intolerance or inadequate response.
    Documentation Required

    Preferred-Product Trial or Exception Documentation

    If the preferred-product sequence cannot be completed, submit documentation supporting the exception.

    • Document trial and failure, intolerance, or inadequate response.
    • Alternatively, document clinical evidence or patient history showing that a preferred product is likely to be ineffective or cause an adverse reaction.
    Documentation Required

    Coverage and Medical-Necessity Documentation

    Before requesting coverage, provide information establishing that the service is a covered benefit and medically necessary under the member’s contract and applicable criteria.

    • Confirm benefits are available under the member’s contract or certificate.
    • Submit documentation showing that medical-necessity criteria and guidelines are met.
    Documentation Required

    Previous Authorization for Transition Period

    For an ongoing course of treatment authorized by a previous health plan, provide the prior authorization documentation for the transition period before requesting continued services.

    • Document the previous health plan’s authorization for the ongoing treatment.
    • The transition period is 90 days.
    • The course of treatment must otherwise be covered under the Blue Advantage health plan.
    Denial Risk

    Preferred-Product Criterion Not Met

    Requests for the listed non-preferred trastuzumab products may be denied as not medically necessary when the required preferred-product criterion is not met.

    • Affected products include Herceptin, Kanjinti, Herzuma, Hercessi, and Herceptin Hylecta.
    • Document trials and failures of Ontruzant, Ogivri, and Trazimera, or a qualifying clinical exception.
    Denial Risk

    Investigational Use

    Investigational or experimental services are not covered unless an applicable Medicare exception requires coverage.

    • Noncoverage includes drugs, devices, procedures, or services provided under the investigational arm of a clinical trial or study.
    • Limited exceptions apply to qualifying Category A and Category B IDE studies as described in the policy.
    Documentation Required

    Contract and Medical-Necessity Requirements

    Coverage is available only when the applicable benefit exists and medical-necessity criteria and guidelines are satisfied.

    • Verify that benefits are available in the member’s contract or certificate.
    • Ensure the requested treatment, drug, device, or biological product meets applicable criteria and guidelines.
    Denial Risk

    Medical Necessity and Cost-Effectiveness

    Services may be denied when they are not clinically appropriate or effective, are primarily for convenience, or are more costly than an equally effective alternative.

    • The service must be appropriate in type, frequency, extent, level of care, site, and duration.
    • The service must be effective for the patient’s condition.
    • The service must not be primarily for comfort or convenience and must not be more costly than an equivalent alternative.
    Documentation Required

    Transition Authorization Documentation

    Before honoring an ongoing authorization from a previous health plan during the transition period, obtain and submit documentation of that authorization.

    • Documentation must be provided by the member or provider.
    • The ongoing course of treatment must otherwise be a covered service under the Blue Advantage health plan.
    • Apply the 90-day transition requirement.

    Trazimera is a preferred trastuzumab biosimilar to Herceptin. Coverage of non-preferred trastuzumab products requires a trial and failure of Trazimera unless clinical evidence or patient history indicates it would be ineffective or cause an adverse reaction.

    Billing Rule

    Biosimilar substitution may be covered

    An FDA-approved biosimilar may be covered as an alternate to its existing FDA-approved reference product. Use of a biosimilar as an alternative to a reference product is not considered step therapy by the Health Plan.

    Herceptin Hylecta is a subcutaneous formulation of Herceptin, with clinical trials showing similar efficacy and safety to intravenous Herceptin.
    Biosimilar
    FDA definitionA biosimilar is a biological product that has no clinically meaningful differences from an existing FDA-approved reference product.
    Approval standardFDA-approved biosimilars meet the FDA's rigorous standards for approval for the indications described in product labeling.
    Safety and effectivenessOnce approved by the FDA, the biosimilar's safety and effectiveness have been established, as they have been for the reference product.
    Coverage relationshipCoverage of a biosimilar as an alternate to its reference product is not considered step therapy by the Health Plan.
    Nationally accepted standards of medical practice
    Scientific evidenceCredible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community.
    Specialty-society recommendationsRecommendations of relevant physician specialty societies.
    Clinical expertiseThe views of physicians practicing in relevant clinical areas.
    Other factorsAny other relevant factors.
    Medical necessity
    Clinical appropriatenessThe service is clinically appropriate in type, frequency, extent, level of care, site, and duration.
    EffectivenessThe service is effective for the patient's illness, injury, or disease.
    Patient or provider convenienceThe service is not primarily for the personal comfort or convenience of the patient, physician, or other healthcare provider.
    Cost-effectivenessThe service is not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results.
    Governing requirementsThe definition is subject to applicable contract language, federal and state law, and Medicare coverage requirements.